Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma.

The article discusses a clinical trial, NCT06676319, focusing on the treatment of asthma in adults with high-risk asthma who are not eligible for biologic treatments. The study aims to evaluate the efficacy, safety, and tolerability of add-on therapy with SC lunsekimig compared to a placebo. The trial duration is approximately 64 weeks for some participants and 60 weeks for others, with the investigational treatment lasting up to 52 weeks and involving 18 visits. The study includes various outcome measures related to asthma exacerbation events, lung function, asthma control, and adverse events. [Extracted from the article]